Time schedule-dependent effect of the CK2 inhibitor TBB on PC-3 human prostate cancer cell viability

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 281-285

  Orzechowska, Emilia ^a   Kozłowska, Ewa ^a   Staroń, Krzysztof ^a   Trzcińska Danielewicz, Joanna ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Camptothecin; CK2 kinase; PC 3 cells; Tetrabromobenzotriazole; TRAIL

Indexed keywords

4,5,6,7 TETRABROMOBENZOTRIAZOLE; CAMPTOTHECIN; CASEIN KINASE II; DEOXYGLUCOSE; DNA TOPOISOMERASE; GLUCOSE 6 PHOSPHATE ISOMERASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLYCOLYSIS; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRIAZOLES;

EID: 84855275526     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1500     Document Type: Article

References (40)

1. St-Denis NA and Litchfield DW: From birth to death: The role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66: 1817-1829, 2009.
2. Padmanabha R, Chen-Wu JLP, Hanna DE and Glover CVC: Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae. Mol Cell Biol 10: 4089-4099, 1990.
3. Pepperkok R, Lorenz P, Ansorge W and Pyerin W: Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 269: 6986-6991, 1994. (Pubitemid 24191097)
4. Tripodi F, Zinzalla V, Vanoni M, Alberghina L and Coccetti P: In CK2 inactivated cells the cyclin dependent kinase inhibitor Sic1 is involved in cell-cycle arrest before the onset of S phase. Biochem Biophys Res Commun 359: 921-927, 2007. (Pubitemid 46946905)
5. Homma MK and Homma Y: Cell cycle and activation of CK2. Mol Cell Biochem 316: 49-55, 2008.
6. Li H, Liu XS, Yang X, Wang Y, Wang Y, Turner JR and Liu X: Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J 29: 2953-2965, 2010.
7. Coccetti P, Tripodi F, Tedeschi G, Nonnis S, Marin O, Fantinato S, Cirulli C, Vanoni M and Alberghina L: The CK2 phosphorylation of catalytic domain of Cdc34 modulates its activity at the G1 to S transition in Saccharomyces cerevisiae. Cell Cycle 7: 1391-1401, 2008. (Pubitemid 351872578)
8. Izeradjene K, Douglas L, Delaney A and Houghton JA: Casein kinase II (CK2) enhances death-inducing signaling complex (DISC) activity in TRAIL-induced apoptosis in human colon carcinoma cell lines. Oncogene 24: 2050-2058, 2005. (Pubitemid 40516198)
9. Wang G, Ahmad KA and Ahmed K: Modulation of death receptor-mediated apoptosis by CK2. Mol Cell Biochem 274: 201-205, 2005. (Pubitemid 41001516)
10. Wang G, Ahmad KA and Ahmed K: Role of protein kinase CK2 in the regulation of tumor necrosis factor-related apoptosis inducing ligand-induced apoptosis in prostate cancer cells. Cancer Res 66: 2242-2249, 2006.
11. Duncan JS, Turowec JP, Vilk G, Li SSC, Gloor GB and Litchfield DW: Regulation of cell proliferation and survival: Convergence of protein kinases and caspases. Biochim Biophys Acta 1804: 505-510, 2010.
12. Desagher S, Osen-Sand A, Montessuit S, Magnenat E, Vilbois F, Hochmann A, Journot L, Antonsson B and Martinou JC: Phosphorylation of Bid by casein kinases I and II regulates its cleavage by caspase 8. Mol Cell 8: 601-611, 2001. (Pubitemid 32946937)
13. Krippner-Heidenreich A, Talanian RV, Sekul R, Kraft R, Thole H, Ottleben H and Luscher B: Targeting of the transcription factor Max during apoptosis: phosphorylation-regulated cleavage by caspase-5 at an unusual glutamic acid residue in position P1. Biochem J 358: 705-715, 2001. (Pubitemid 32896958)
14. Maccario H, Perera NM, Davidson L, Downes CP and Leslie NR: PTEN is destabilized by phosphorylation on Thr366. Biochem J 405: 439-444, 2007.
15. Shin S, Lee Y, Kim W, Ko H, Choi H and Kim K: Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J 24: 3532-3542, 2005. (Pubitemid 41509361)
16. Llobet D, Eritja N, Encinas M, Llecha N, Yeramian A, Pallares J, Sorolla A, Gonzalez-Tallada FJ, Matias-Guiu X and Dolcet X: CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 27: 2513-2524, 2008. (Pubitemid 351550887)
17. Tapia JC, Torres VA, Rodriguez DA, Leyton L and Quest AFG: Casein kinase 2 (CK2) increases survivin expression via enhanced β-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103: 15079-15084, 2006. (Pubitemid 44583167)
18. Scaglioni PP, Yung TM, Choi SC, Baldini C, Konstantinidou G and Pandolfi PP: CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem 316: 149-154, 2008.
19. Chakrabortya A, Werner JK Jr, Koldobskiya MA, Mustafaa AK, Juluria KR, Pietropaolia J, Snowman AM and Snyder SH: Casein kinase-2 mediates cell survival through phosphorylation and degradation of inositol hexakisphosphate kinase-2. Proc Natl Acad Sci USA 108: 2205-2209, 2011.
20. Wang G, Unger G, Ahmad KA, Slaton JW and Ahmed K: Downregulation of CK2 induces apoptosis in cancer cells - A potential approach to cancer therapy. Mol Cell Biochem 274: 77-84, 2005. (Pubitemid 41001503)
21. Hanif IM, Hanif IM, Shazib MA, Ahmad KA and Pervaiz S: Casein Kinase II: An attractive target for anti-cancer drug design. Int J Biochem Cell Biol 42: 1602-1605, 2010.
22. Ruzzene M, Penzo D and Pinna LA: Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47, 2002. (Pubitemid 34538944)
23. Zwicker F, Ebert M, Huber PE, Debus J and Weber KJ: A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells. Radiat Oncol 6: 15, 2011.
24. Schneider CC, Hessenauer A, Montenarh M and Götz C: p53 is dispensable for the induction of apoptosis after inhibition of protein kinase CK2. Prostate 70: 126-134, 2010.
25. Sarno S, Ruzzene M, Frascella P, Pagano MA, Meggio F, Zambon A, Mazzorana M, Di Maira G, Lucchini V and Pinna LA: Development and exploitation of CK2 inhibitors. Mol Cell Biochem 274: 69-76, 2005. (Pubitemid 41001502)
26. Bandyopadhyay K and Gjerset RA: Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. Biochemistry 50: 704-714, 2011.
27. Meggio F and Pinna LA: One-thousand-and-one substrates of protein kinase CK2? FASEB J 17: 349-368, 2003. (Pubitemid 36292951)
28. Salvi M, Sarno S, Cesaro L, Nakamura H and Pinna LA: Extraordinary pleiotropy of protein kinase CK2 revealed by weblogo phosphoproteome analysis. Biochim Biophys Acta 1793: 847-859, 2009.
29. Pinna LA and Ruzzene M: How do protein kinases recognize their substrates? Biochim Biophys Acta 1314: 191-225, 1996.
30. Tawfic S, Yu S, Wang H, Faust R, Davis A and Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol 16: 573-582, 2001. (Pubitemid 32297655)
31. Hessenauer A, Montenarh M and Götz C: Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 22: 1263-1270, 2003.
32. Hessenauer A, Carolin C, Schneider CC, Götz C and Montenarh M: CK2 inhibition induces apoptosis via the ER stress response. Cell Signalling 23: 145-151, 2011.
33. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987. (Pubitemid 17158816)
34. Xiao D and Singh SV: Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 62: 3615-3619, 2002. (Pubitemid 34728834)
35. Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C, Auberger P, Pende M and Ricci JE: Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29: 1641-1652, 2010.
36. Li GY, Fan B and Su GF: Acute energy reduction induces caspase-dependent apoptosis and activates p53 in retinal ganglion cells (RGC-5). Exp Eye Res 89: 581-589, 2009.
37. Qin JZ, Xin H and Nickoloff BJ: 2-Deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose. Biochem Biophys Res Commun 401: 293-299, 2010.
38. Munoz-Pinedo C, Ruiz-Ruiz C, Ruiz de Almodovar C, Palacios C and Lopez-Rivas A: Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 278: 12759-12768, 2003. (Pubitemid 36800039)
39. Nam SY, Amoscato A and Lee YJ: Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21: 337-346, 2002. (Pubitemid 34123796)
40. Yanagawa T, Funasaka T, Tsutsumi S, Raz T, Tanaka N and Raz A: Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation. J Biol Chem 280: 10419-10426, 2006.